Home/Filings/4/0002048588-26-000002
4//SEC Filing

Feider Stephen 4

Accession 0002048588-26-000002

CIK 0001674632other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 6:03 PM ET

Size

8.9 KB

Accession

0002048588-26-000002

Insider Transaction Report

Form 4
Period: 2026-01-02
Feider Stephen
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-02$5.10/sh+20,000$102,00062,614 total
  • Sale

    Common Stock

    2026-01-02$29.53/sh20,000$590,68042,614 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2026-01-0220,00049,695 total
    Exercise: $5.10Exp: 2033-09-13Common Stock (20,000 underlying)
Footnotes (3)
  • [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
  • [F2]The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

Issuer

Beta Bionics, Inc.

CIK 0001674632

Entity typeother

Related Parties

1
  • filerCIK 0002048588

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 6:03 PM ET
Size
8.9 KB